Multi-modality management of hypertrophic cardiomyopathy-Reference-Cited by-同舟云学术

Multi-modality management of hypertrophic cardiomyopathy

Published:2023-01-01 Issue:1 Volume:51 Page:2-11
ISSN:2154-8331
Container-title:Hospital Practice
language:en
Short-container-title:Hospital Practice

Author:

Rao Shiavax J.¹^ORCID,Iqbal Shaikh B.¹^ORCID,Kanwal Arjun S.²^ORCID,Aronow Wilbert S.³^ORCID,Naidu Srihari S.⁴

Affiliation:

1. Department of Medicine, MedStar Union Memorial Hospital, Baltimore, USA

2. Department of Cardiology, Westchester Medical Center, Valhalla, USA

3. Department of Cardiology, Westchester Medical Center and Department of Medicine, New York Medical College, Valhalla, USA

4. Hypertrophic Cardiomyopathy Center, Cardiac Catheterization Laboratory, Department of Cardiology, Westchester Medical Center and Department of Medicine, New York Medical College, Valhalla, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/21548331.2022.2162297

Reference89 articles.

1. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy

2. The Many Faces of Hypertrophic Cardiomyopathy: From Developmental Biology to Clinical Practice

3. Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy

4. Hypertrophic Cardiomyopathy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy;Cardiology in Review;2023-10-25

2. Looking Back at 30 Years of Alcohol Septal Ablation and Looking Forward to the Future;Canadian Journal of Cardiology;2023-09